IPH4502 Phase 1 Clinical Trial for Solid Tumors Expressing Nectin-4
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxModified Virus Shows Promise in Shrinking Tumors and Halting Cancer Growth
/0 Comments/in Not PCa related/by MaxGoogle’s AI-Driven Breakthrough: The Future of Drug Discovery
/0 Comments/in Artificial Intelligence/by MaxWe can’t always win: LAVA-1207 Development Discontinued, Not Related to Safety Issues
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 3/2025
/0 Comments/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi, fellow fighters! Ok, this week I had to take some time off for my PET scan and checkup, so I haven’t gathered as much information as usual to share with you. Nonetheless, what I found is still very interesting and promising! […]
PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair
/0 Comments/in Review/by MaxUpdate on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxUMass Scientists Develop Novel Bacteria-Based Cancer Therapy
/0 Comments/in Oncolytic, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond July 29, 2025
- AI Platform Aims to Revolutionize Cancer Immunotherapy July 28, 2025
- FDA Clears First-in-Human Phase 1 Trial: RV-01 Targeting Solid Tumors July 28, 2025
- Phase 1 Trial For BL-M14D1 For Neuroendocrine Cancers July 28, 2025